Collegium Pharmaceutical (COLL) vs. Its Peers Head to Head Analysis

Collegium Pharmaceutical (NASDAQ:COLL) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Collegium Pharmaceutical to related businesses based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Collegium Pharmaceutical and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1	1	6	1	2.78
Collegium Pharmaceutical Competitors	7750	13840	25681	1031	2.41

Collegium Pharmaceutical currently has a consensus target price of $48.71, indicating a potential upside of 102.81%. As a group, “Pharmaceuticals” companies have a potential upside of 24.05%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than its rivals.

Earnings & Valuation

This table compares Collegium Pharmaceutical and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21 million	$62.87 million	19.37
Collegium Pharmaceutical Competitors	$3.55 billion	$3.19 billion	546.79

Collegium Pharmaceutical’s rivals have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Collegium Pharmaceutical and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Collegium Pharmaceutical Competitors	-2,380.63%	-221.06%	-16.01%

Institutional and Insider Ownership

32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s rivals have a beta of -4.34, suggesting that their average stock price is 534% less volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats its rivals on 8 of the 13 factors compared.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.